Assertio Holdings ISIN: US04546C2052 Forum: Aktien User: Summer.76

https://finance.yahoo.com/news/assertio-holdings-joins-russell-3000-110000866.html

ASSERTIO REPORTS FIRST QUARTER 2023 FINANCIAL RESULTS, RAISES FULL YEAR 2023 OUTLOOK https://investor.assertiotx.com/news/news-details/2023/Assertio-Reports-First-Quarter-2023-Financial-Results-Raises-Full-Year-2023-Outlook/default.aspx

https://finance.yahoo.com/news/assertio-holdings-inc-acquire-spectrum-100000644.html

Did you see the fusion with **** pharma?

https://finance.yahoo.com/news/assertio-provides-educational-grant-lennox-130000477.html

🍀

ASSERTIO REPORTS FOURTH QUARTER AND FULL YEAR 2022 FINANCIAL RESULTS https://investor.assertiotx.com/news/news-details/2023/Assertio-Reports-Fourth-Quarter-and-Full-Year-2022-Financial-Results/default.aspx Net Product Sales Increase 55% in the Fourth Quarter, 42% for the Full Year Full Year Net Income Increases to $109.6 Million, Non-GAAP Adjusted EBITDA Increases to $101.6 Million Cash Flows from Operations Was $26.7 Million for the Fourth Quarter and $78.6 Million for the Full Year

Assertio Holdings: Compelling Income Opportunity Apart From Upside Potential https://seekingalpha.com/article/4581797-assertio-holdings-compelling-income-opportunity-apart-from-upside-potential Summary • Q4 preliminary results illustrate the best product sales quarter for the past 5 years. • Technicals, valuation, and profitability trends all point to rising prices for the stock. • An aggressive covered call strategy is an excellent play here for both income and capital appreciation purposes. ...

Assertio Announces Exchange Offer of $30 Million of its Currently Outstanding 6.50% Convertible Senior Notes Due 2027 https://finance.yahoo.com/news/assertio-announces-exchange-offer-30-121400733.html

https://finance.yahoo.com/news/assertio-holdings-inc-announces-preliminary-120000679.html

https://seekingalpha.com/article/4571315-assertio-holdings-scores-with-new-broadly-covered-asset Assertio Holdings Scores With New Broadly-Covered Asset Summary • Assertio Holdings, Inc. got the rights to Sympazan in October. • Most Medicare plans cover it. • Meanwhile, Assertio Holdings, Inc.'s lead product Indocin is a favored brand by the nation's #1 health insurance company. ...

https://www.globenewswire.com/news-release/2023/01/09/2585674/0/en/Assertio-Holdings-Inc-Announces-FDA-Orange-Book-Listing-for-New-Sympazan-Oral-Film-Patent.html

https://investor.assertiotx.com/news/news-details/2022/Assertio-Holdings-Inc.-to-Host-Investor-and-Business-Development-Meetings-January-9-11-2023-in-San-Francisco/default.aspx

https://finance.yahoo.com/news/assertio-increases-full-net-product-123000490.html

Assertio Reports Third Quarter 2022 Financial Results https://finance.yahoo.com/news/assertio-reports-third-quarter-2022-210100129.html Net Product Sales Increase 32% Year-Over-Year, Non-GAAP Adjusted EBITDA Increases 36% Increases Guidance for Net Product Sales and Adjusted EBITDA Debt Refinancing Extends Maturity, Reduces Cost and Increases Strategic Flexibility Expects Sympazan to Add $1 Million in Net Product Sales in 4Q

Assertio Holdings, Inc. Signs Exclusive License for Sympazan® (clobazam) Oral Film from Aquestive Therapeutics, Inc. https://www.globenewswire.com/news-release/2022/10/27/2542885/0/en/Assertio-Holdings-Inc-Signs-Exclusive-License-for-Sympazan-clobazam-Oral-Film-from-Aquestive-Therapeutics-Inc.html Trailing 12 Month Revenues of Sympazan Were $9.5 Million Assertio Paid $9.0 Million Upfront, Additional $6.0 Million upon Patent Allowance